ICER and Verdant Research Publish White Paper Examining FDA’s Accelerated Approval Pathway

Key Takeaways

• Stratify surrogate endpoints by predictive validity to prioritize clinical benefit
• Add patient‑experience outcomes to trials for richer benefit‑risk context
• Require FDA to disclose residual uncertainty and obtain informed consent
• Tie drug pricing to evidence level, adjusting as confirmatory data emerge
• Establish formal triggers to reassess or withdraw delayed accelerated approvals

Pulse Analysis

The FDA’s accelerated approval pathway was created to fast‑track innovative drugs, especially for oncology and rare diseases, by allowing market entry based on surrogate endpoints. While the model has delivered breakthroughs, critics argue that inconsistent surrogate validation and prolonged confirmatory trials erode confidence among clinicians, payers, and patients. ICER’s latest white paper builds on its 2021 analysis, underscoring that without tighter evidentiary standards, the pathway risks becoming a loophole for premature market access.

Key recommendations focus on three pillars: scientific rigor, transparency, and economic alignment. By stratifying surrogate markers according to their predictive power, regulators can prioritize therapies most likely to translate into real clinical benefit. Incorporating patient‑reported outcomes alongside traditional endpoints enriches the benefit‑risk narrative, giving clinicians clearer guidance. The paper also urges the FDA to publish residual uncertainty and secure informed consent, ensuring patients understand the provisional nature of the evidence. Coupled with evidence‑linked pricing, these measures aim to synchronize reimbursement with the evolving data landscape.

For the industry, the suggested reforms could reshape launch strategies. Manufacturers may need to invest earlier in robust surrogate validation and plan for dynamic pricing contracts that adjust as confirmatory data mature. Payers stand to gain clearer criteria for coverage decisions, reducing the financial exposure of funding therapies with uncertain efficacy. If adopted, the reforms could restore credibility to accelerated approvals, fostering a more sustainable balance between rapid innovation and accountable evidence generation.